A new study led by Henry Daniell of the School of Dental Medicine investigates a new approach to the oral delivery of exenatide and lixisenatide, two GLP-1 receptor agonists previously approved by the FDA in injectable form, to address these hurdles
Xu P, He Y, Cao X, Valencia-Torres L, Yan X, Saito K, et al
When a compound contacts this tissue and stays there long enough, it passes directly into the bloodstream without going through the stomach or liver first
The research data here comes from clinical trials, emerging endocrinology findings, and the practical experience of people who have navigated this exact combination
Recreational nitrous oxide-related myeloneuropathy in adolescents: a multicenter retrospective case series and systematic literature review
Who May Be a Candidate for GLP-1 Weight-Loss Injections